UK NICE recommends Vifor’s Tavneos for AAV treatment
The recommendation is based on the complete development programme data, including findings from the Phase III ADVOCATE trial.

The recommendation is based on the complete development programme data, including findings from the Phase III ADVOCATE trial.
Vegzelma was found to be similar in terms of safety, efficacy and pharmacokinetics to the reference product.
The vaccine is not advised for usage in people aged 50 years and older.
The approval is based on findings from two Phase III clinical trials and a long-term follow-up study of Zynteglo.
Atomwise is entitled to receive research, development and sales-based milestone payments totalling over $1bn.
The approval is based on findings from two Phase II trials and the UK-sponsored COV-BOOST trial.
Polivy plus R-CHP offered a 27% decline in disease progression, relapse or morality risk in a Phase III clinical trial.
RoosterBio will use its cell and media product portfolio to create scalable processes for hMSC and exosome therapies.
Thank you for subscribing to Pharmaceutical Technology